Century Therapeutics Inc


Century Therapeutics Inc

  • Price (USD)3.03
  • Today's Change-0.16 / -5.02%
  • Shares traded72.16k
  • 1 Year change-63.89%
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-104 is a multi-specific collaboration program for acute myeloid leukemia.

  • Revenue in USD (TTM)5.86m
  • Net income in USD-124.68m
  • Incorporated2018
  • Employees163.00
  • Location
    Century Therapeutics Inc3675 Market StPHILADELPHIA 19104United StatesUSA
  • Phone+1 (215) 981-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centurytx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
AC Immune SA4.35m-76.68m173.13m126.00--1.02--39.83-0.9152-0.91520.05192.020.0195--21.2734,497.03-34.31-18.28-36.35-19.56-----1,764.17-154.12----0.0171-----27.943.06---7.22--
Atara Biotherapeutics Inc57.49m-214.97m173.41m330.00--2.63--3.02-2.08-2.080.55890.67290.1644--107.95172,110.80-61.48-66.89-81.13-78.941.76---373.95-1,664.513.22--0.0127--212.55--32.88---27.00--
Kinnate Biopharma Inc0.00-122.31m173.72m94.00--0.7798-----2.75-2.750.004.780.00----0.00-41.29---46.53--------------0.00-------29.53------
Ocean Biomedical Inc0.00-958.42k175.85m9.00--0.6556-----0.0725-0.07250.007.890.00----0.00-0.873---0.888--------------0.0202-------69.90------
Citius Pharmaceuticals Inc0.00-30.97m176.33m21.00--1.78-----0.2119-0.21190.000.62320.00----0.00-26.70-31.66-28.08-33.78------------0.00-------37.28------
Jasper Therapeutics Inc0.00-49.74m176.52m35.00--1.40-----1.08-
Merrimack Pharmaceuticals Inc0.00-1.68m178.25m----9.32-----0.1231-0.12310.001.340.00-------9.82-42.62-10.12-49.52------------0.00------37.11------
Fulcrum Therapeutics Inc4.05m-108.72m179.72m89.00--0.6066--44.43-2.26-2.260.08134.800.0149--3.2745,449.44-40.17-55.72-42.75-62.36-----2,687.81-1,097.65----0.00---66.90---35.90--0.57--
Century Therapeutics Inc5.86m-124.68m180.53m163.00--0.6461--30.80-2.14-2.140.10084.690.0117----35,957.05-24.77---26.06-------2,127.33-----84.520.0358-------36.64------
Cara Therapeutics Inc43.24m-84.39m183.54m106.00--1.34--4.24-1.57-1.570.80462.530.22932.8710.10407,943.40-44.75-31.98-49.33-36.5682.02---195.16-148.248.34--0.00--81.81115.023.35---5.81--
ADC Therapeutics SA182.40m-198.57m183.87m317.00--4.88--1.01-2.52-2.522.300.46730.34760.14237.18575,400.60-37.84-47.88-44.24-54.3498.83---108.86-352.484.46-5.590.9001--518.89158.9432.27---6.15--
Adaptimmune Therapeutics PLC - ADR71.17m-114.16m183.93m534.00--2.19--2.58-0.7028-0.70280.43480.50650.2011--40.20133,284.60-32.25-40.76-39.49-47.20-----160.39-701.17----0.00--341.50-6.42-4.66--3.52--
GeneDx Holdings Corp223.89m-533.07m184.49m1.10k--0.531--0.824-44.48-44.4816.7213.580.42139.916.35203,538.20-100.30---126.43---7.66---238.09--2.18--0.0764--10.60---123.72------
Aadi Bioscience Inc18.78m-61.88m189.14m80.00--1.30--10.07-2.64-2.640.78245.970.120.84154.54237,670.90-39.54-50.93-43.62-56.0191.03---329.56-405.079.08--0.00--1,258.57--45.03--118.57--
Gracell Biotechnologies Inc (ADR)0.00-86.01m189.60m348.00--0.9728-----1.27-
Immuneering Corp133.26k-51.22m189.68m68.00--1.76--1,423.36-1.94-1.940.0053.690.001--0.94961,825.48-39.38---40.82--49.52---38,437.16------0.00---84.76---50.63------
Data as of May 26 2023. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

29.05%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 20235.29m8.94%
Casdin Capital LLCas of 31 Mar 20233.21m5.42%
DAFNA Capital Management LLCas of 31 Mar 20231.31m2.21%
BlackRock Fund Advisorsas of 31 Mar 20231.27m2.15%
Avidity Partners Management LPas of 31 Mar 20231.27m2.14%
Federated Global Investment Management Corp.as of 31 Mar 20231.16m1.97%
Baker Bros. Advisors LPas of 31 Mar 20231.15m1.94%
The Vanguard Group, Inc.as of 31 Mar 20231.09m1.84%
Deep Track Capital LPas of 31 Mar 20231.02m1.73%
Geode Capital Management LLCas of 31 Mar 2023421.18k0.71%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.